|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cooper JS, Guo MD, Herskovic A, Macdonald
JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler
JJ, Spencer S, et al; Radiation Therapy Oncology Group.
Chemoradiotherapy of locally advanced esophageal cancer: Long-term
follow-up of a prospective randomized trial (RTOG 85-01). JAMA.
281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Linkous AG and Yazlovitskaya EM: Novel
radiosensitizing anticancer therapeutics. Anticancer Res.
32:2487–2499. 2012.PubMed/NCBI
|
|
5
|
Sjoquist KM, Burmeister BH, Smithers BM,
Zalcberg JR, Simes RJ, Barbour A and Gebski V; Australasian
Gastro-Intestinal Trials Group. Survival after neoadjuvant
chemotherapy or chemoradiotherapy for resectable oesophageal
carcinoma: An updated meta-analysis. Lancet Oncol. 12:681–692.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dent P, Yacoub A, Contessa J, Caron R,
Amorino G, Valerie K, Hagan MP, Grant S and Schmidt-Ullrich R:
Stress and radiation-induced activation of multiple intracellular
signaling pathways. Radiat Res. 159:283–300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barcellos-Hoff MH, Park C and Wright EG:
Radiation and the microenvironment - tumorigenesis and therapy. Nat
Rev Cancer. 5:867–875. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsukamoto H, Shibata K, Kajiyama H,
Terauchi M, Nawa A and Kikkawa F: Irradiation-induced
epithelial-mesenchymal transition (EMT) related to invasive
potential in endometrial carcinoma cells. Gynecol Oncol.
107:500–504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wild-Bode C, Weller M, Rimner A, Dichgans
J and Wick W: Sublethal irradiation promotes migration and
invasiveness of glioma cells: Implications for radiotherapy of
human glioblastoma. Cancer Res. 61:2744–2750. 2001.PubMed/NCBI
|
|
10
|
Marie-Egyptienne DT, Lohse I and Hill RP:
Cancer stem cells, the epithelial to mesenchymal transition (EMT)
and radioresistance: Potential role of hypoxia. Cancer Lett.
341:63–72. 2013. View Article : Google Scholar
|
|
11
|
He E, Pan F, Li G and Li J: Fractionated
ionizing radiation promotes epithelial-mesenchymal transition in
human esophageal cancer cells through PTEN deficiency-mediated Akt
activation. PLoS One. 10:e01261492015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park JK, Jang SJ, Kang SW, Park S, Hwang
SG, Kim WJ, Kang JH and Um HD: Establishment of animal model for
the analysis of cancer cell metastasis during radiotherapy. Radiat
Oncol. 7:1532012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou YC, Liu JY, Li J, Zhang J, Xu YQ,
Zhang HW, Qiu LB, Ding GR, Su XM, Mei-Shi, et al: Ionizing
radiation promotes migration and invasion of cancer cells through
transforming growth factor-beta-mediated epithelial-mesenchymal
transition. Int J Radiat Oncol Biol Phys. 81:1530–1537. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bailey CJ and Turner RC: Metformin. N Engl
J Med. 334:574–579. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar :
|
|
18
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dowling RJ, Niraula S, Stambolic V and
Goodwin PJ: Metformin in cancer: Translational challenges. J Mol
Endocrinol. 48:R31–R43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chaudhary SC, Kurundkar D, Elmets CA,
Kopelovich L and Athar M: Metformin, an antidiabetic agent reduces
growth of cutaneous squamous cell carcinoma by targeting mTOR
signaling pathway. Photochem Photobiol. 88:1149–1156. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bao B, Azmi AS, Ali S, Zaiem F and Sarkar
FH: Metformin may function as anti-cancer agent via targeting
cancer stem cells: The potential biological significance of
tumor-associated miRNAs in breast and pancreatic cancers. Ann
Transl Med. 2:592014.PubMed/NCBI
|
|
22
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufí S, Del Barco S, Martin-Castillo B and Menendez JA: Metformin
regulates breast cancer stem cello ntogeny by transcriptional
regulation of the epithelial-mesenchymal transition (EMT) status.
Cell Cycle. 9:3831–3838. 2014. View Article : Google Scholar
|
|
24
|
Cufí S, Vazquez-Martin A,
Oliveras-Ferraros C, Martin-Castillo B, Joven J and Menendez JA:
Metformin against TGFβ-induced epithelial-to-mesenchymal transition
(EMT): From cancer stem cells to aging-associated fibrosis. Cell
Cycle. 9:4461–4468. 2010. View Article : Google Scholar
|
|
25
|
Westermarck J and Kähäri VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999.PubMed/NCBI
|
|
26
|
Saitoh M, Shirakihara T and Miyazono K:
Regulation of the stability of cell surface E-cadherin by the
proteasome. Biochem Biophys Res Commun. 381:560–565. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Morrison CD, Parvani JG and Schiemann WP:
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer
Lett. 341:30–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mimeault M and Batra SK: Hypoxia-inducing
factors as master regulators of stemness properties and altered
metabolism of cancer- and metastasis-initiating cells. J Cell Mol
Med. 17:30–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lamouille S and Derynck R: Cell size and
invasion in TGF-beta-induced epithelial to mesenchymal transition
is regulated by activation of the mTOR pathway. J Cell Biol.
178:437–451. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen L, Li M, Li Q, Wang CJ and Xie SQ:
DKK1 promotes hepatocellular carcinoma cell migration and invasion
through β-catenin/MMP7 signaling pathway. Mol Cancer. 12:1572013.
View Article : Google Scholar
|
|
32
|
Zhang X, Li X, Zhang N, Yang Q and Moran
MS: Low doses ionizing radiation enhances the invasiveness of
breast cancer cells by inducing epithelial-mesenchymal transition.
Biochem Biophys Res Commun. 412:188–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zong H, Yin B, Zhou H, Cai D, Ma B and
Xiang Y: Inhibition of mTOR pathway attenuates migration and
invasion of gallbladder cancer via EMT inhibition. Mol Biol Rep.
41:4507–4512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han B, Cui H, Kang L, Zhang X, Jin Z, Lu L
and Fan Z: Metformin inhibits thyroid cancer cell growth,
migration, and EMT through the mTOR pathway. Tumour Biol.
36:6295–6304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Koeck S, Amann A, Huber JM, Gamerith G,
Hilbe W and Zwierzina H: The impact of metformin and salinomycin on
transforming growth factor β-induced epithelial-to-mesenchymal
transition in non-small cell lung cancer cell lines. Oncol Lett.
11:2946–2952. 2016.PubMed/NCBI
|
|
36
|
Sanli T, Rashid A, Liu C, Harding S,
Bristow RG, Cutz JC, Singh G, Wright J and Tsakiridis T: Ionizing
radiation activates AMP-activated kinase (AMPK): A target for
radiosensitization of human cancer cells. Int J Radiat Oncol Biol
Phys. 78:221–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Storozhuk Y, Hopmans SN, Sanli T, Barron
C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G and Tsakiridis T:
Metformin inhibits growth and enhances radiation response of
non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J
Cancer. 108:2021–2032. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bussink J, van der Kogel AJ and Kaanders
JH: Activation of the PI3-K/AKT pathway and implications for
radioresistance mechanisms in head and neck cancer. Lancet Oncol.
9:288–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bodmer M, Meier C, Krähenbühl S, Jick SS
and Meier CR: Metformin, sulfonylureas, or other antidiabetes drugs
and the risk of lactic acidosis or hypoglycemia: A nested
case-control analysis. Diabetes Care. 31:2086–2091. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hadad S, Iwamoto T, Jordan L, Purdie C,
Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, et al:
Evidence for biological effects of metformin in operable breast
cancer: A pre-operative, window-of-opportunity, randomized trial.
Breast Cancer Res Treat. 128:783–794. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Goodwin PJ, Stambolic V, Lemieux J, Chen
BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA,
Mayer IA, et al: Evaluation of metformin in early breast cancer: A
modification of the traditional paradigm for clinical testing of
anti-cancer agents. Breast Cancer Res Treat. 126:215–220. 2011.
View Article : Google Scholar
|
